Addanki, Sumanth and Butler, Henry N.. 2014. Activating Actavis: Economic Issues in Applying the Rule of Reason to Reverse Payment Settlements. Minnesota Journal of Law, Science & Technology, 15(1), 77–94.Google Scholar

Addanki, Sumanth and Daskin, Alan J.. 2008. Patent Settlement Agreements. ABA Section of Antitrust Law, 3, 2127–53.Google Scholar

Cotter, Thomas F. 2004. Antitrust Implications of Patent Settlements Involving Reverse Payments: Defending a Rebuttable Presumption of Illegality in Light of Some Recent Scholarship. Antitrust Law Journal, 71(3), 1069–97.Google Scholar

Cramer, Eric L. and Berger, Daniel. 2004. The Superiority of Direct Proof of Monopoly Power and Anticompetitive Effects in Antitrust Cases Involving Delayed Entry of Generic Drugs. University of San Francisco Law Review, 39, 81–140.Google Scholar

Drake, Keith M., Starr, Martha A., and McGuire, Thomas. 2014. Do “Reverse Payment” Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay? NBER Working Paper No. 20292. July.Google Scholar

Edlin, Aaron, Hemphill, Scott, Hovenkamp, Herbert, and Shapiro, Carl. 2013. Activating Actavis. Antitrust Magazine, 28(1), 16–23.Google Scholar

Elhauge, Einer and Krueger, Alex. 2012. Solving the Patent Settlement Puzzle. Texas Law Review, 91, 283–330.Google Scholar

Federal Trade Commission. 2006. Prepared Statement of the Federal Trade Commission Before the Special Committee on Aging of the United States Senate on Barriers to Generic Entry. Available at www.ftc.gov/sites/default/files/documents/public_statements/prepared-statement-federal-trade-commission-generic-drug-entry/p052103barrierstogenericentrytestimonysenate07202006.pdf.Google Scholar

Federal Trade Commission. 2015. Brief for Amicus Curiae Federal Trade Commission Supporting Plaintiff-Appellant in Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al.. Available at www.ftc.gov/system/files/documents/amicus_briefs/mylan-pharmaceuticals-inc.v.warner-chilcott-plc-et-al./151001mylanamicusbrief.pdf.Google Scholar

Golden Gate Pharmacy Services, Inc. v. Pfizer, Inc., No. 10–15978 (9th Cir. May 19, 2011).Google Scholar

Harris, Barry C., Murphy, Kevin M., Willig, Robert D., and Wright, Matthew B.. 2014. Activating Actavis: A More Complete Story. Antitrust Magazine, 28(2), 83–9.Google Scholar

Heading for the Emergency Room. 2009. The Economist, June 25. Available at www.economist.com/node/13899647.Google Scholar

Hirsh, Merrill and Dorfman, Dan Zoloth. 2005. I Didn’t Say Orphan Often: The Benefits of a Bright-Line Rule Barring Brand to Generic Payments in Hatch-Waxman Patent Settlements. Antitrust Health Care Chronicle, 19(2).Google Scholar

Lamberti, Mary J. and Getz, Kenneth. 2015. Profiles of New Approaches to Improving the Efficiency and Performance of Pharmaceutical Drug Development. Tufts Center for the Study of Drug Development White Paper. Available at http://csdd.tufts.edu/files/uploads/CSSD_PhRMAWhitePaperNEWEST.pdf.Google Scholar

Langenfeld, James. 2013. Evaluating the Size of “Reverse Payments” in Light of the Supreme Court’s Decision in FTC v. Actavis. CPI Antitrust Chronicle. Available at www.competitionpolicyinternational.com/evaluating-the-size-of-reverse-payments-in-light-of-the-supreme-court-s-decision-in-ftc-v-actavis-2/.Google Scholar

Leffler, Keith B. and Leffler, Cristofer I.. 2002. Want to Pay a Competitor to Exit the Market? Settle a Patent Infringement Case; An Argument for Per Se Condemnation of Payments by the Patent Holder. ABA Section of Antitrust Law Economics Committee Newsletter, Spring, 26–35.Google Scholar

Meijer, Inc. v. Barr Pharmaceuticals, Inc., 572 F. Supp. 2d 38 (D.C. 2008).Google Scholar

Mylan Pharmaceuticals, Inc. v. Warner Chilcott plc, et al. Civ. No. 12–3824 (E.D. Pa. Apr. 16, 2015).Google Scholar

National Science Foundation. 2015. Business Research and Development and Innovation: 2012. Available at www.nsf.gov/statistics/2016/nsf16301/.Google Scholar

Orszag, Jonathan. 2013. Statement of Jon Orszag Before the Committee on Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights. Available at www.judiciary.senate.gov/imo/media/doc/CHRG-113shrg87818.pdf.Google Scholar

Padilla, Jorge and Meunier, Valerie. 2015. Should Reverse Payment Patent Settlements Be Prohibited Per Se? Available at http://ssrn.com/abstract=2604071.Google Scholar

Robbins, Gary, Robbins, Aldonna, and Goodman, John. 1994. Inefficiency in the U.S. Health Care System: What Can We Do? NCPA Policy Report No. 182. Available at www.ncpa.org/pdfs/st182.pdf.Google Scholar

Schering-Plough Corp. v. FTC, 402 F.3d 1056, 1060 (11th Cir. 2005).Google Scholar

Shapiro, Carl F. 2003. Antitrust Limits to Patent Settlements. RAND Journal of Economics, 34(1), 391–411.Google Scholar

UK National Health Service. 2014. Medicines information – Licensing. Available at www.nhs.uk/conditions/Medicinesinfo/pages/safetyissues.aspx.Google Scholar

US Food and Drug Administration. 2014. “Off-Label” and Investigational Use of Marketed Drugs, Biologics, and Medical Devices – Information Sheet. Available at www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm.Google Scholar

US Food and Drug Administration. 2015. Applications for FDA Approval to Market a New Drug. Available at www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=314.Google Scholar

Vivian, Jesse C. 2008. Generic-Substitution Laws. U.S. Pharmacist. Available at www.uspharmacist.com/content/s/44/c/9787/.Google Scholar